Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2

Status

Completed 4

Sponsor Class

INDUSTRY 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4Lymphoid 4Genitourinary 4Other hematologic neoplasm 3Sarcoma 1Plasma cell 1Other solid neoplasm 1Head & Neck 1Endocrine 1CNS 1

Conditions

Prostatic Neoplasms 3Neoplasms 1Neoplasm Metastasis 1Hormone Refractory Prostate Cancer 1Disease 1

Interventions

Docetaxel 205Prednisone 151enzalutamide 128Gemcitabine 123Radiotherapy 117Sunitinib 112Cisplatin 103Leuprolide 98pembrolizumab 96Abiraterone Acetate 94bicalutamide 87Nivolumab 85Goserelin 83Sorafenib 80Paclitaxel 79Carboplatin 77Everolimus 72Bevacizumab 71Magnetic Resonance Spectroscopy 66acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 61pazopanib 56radium Ra 223 dichloride 50Ipilimumab 49Zoledronic Acid 47Cyclophosphamide 44Radiosurgery 43Filgrastim 42abiraterone 41gallium 68 PSMA-11 40Surveys and Questionnaires 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × gossypol acetic acid × Genitourinary × Clear all
NCT00666666 2014-12-18

R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Completed
55 enrolled 13 charts
Genitourinary

Prostatic Neoplasms

NCT00286793 2011-06-29

Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC

Ascenta Therapeutics

Phase 1/2 Completed
76 enrolled
Genitourinary

Neoplasms, Prostatic Neoplasms

NCT00571675 2010-11-09

A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)

Ascenta Therapeutics

Phase 2 Completed
220 enrolled
Genitourinary

Disease, Neoplasm Metastasis, Prostatic Neoplasms

NCT00286806 2010-08-24

A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer

Ascenta Therapeutics

Phase 1/2 Completed
27 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡